| 03.16.22 | Sanofi taps Blackstone for $300M for subcut Sarclisa R&D; Novo Nordisk expands MIT oral biologic pact

Click here to subscribe to Fiercebiotech.com

2 years ago

Html
Text

Webinar: Exploring Pectin and the Advancement of Delayed Release Technology

Tuesday, March 22 | 11am ET / 8am PT

This webinar provides an overview of why the properties and structure of pectin are well suited for site-specific delivery as well as provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications. Register now.

Today's Rundown

Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa Novo Nordisk adds bioelectronics, biosensors and stimuli-responsive delivery devices to scope of MIT pact Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test MHRA request about ultrasound activation system holds up Exact Therapeutics’ solid tumor trial Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

Featured Story

Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisa

By Nick Paul Taylor

Sanofi has turned to Blackstone Life Sciences for help developing a subcutaneous formulation of multiple myeloma drug Sarclisa. Blackstone is putting up $300 million to fund development of the formulation in return for a chance to receive royalties on future subcutaneous sales.

Webinar: At-Home Drug Delivery of Large Molecule Medicines - The Future Is Now

Wednesday, March 23 | 11am ET / 8am PT

A revolution in drug delivery convenience is upon us. Join commercial, R&D, and CMC biopharmaceutical leaders as we discuss technologies that can aid at-home patient-administered drug delivery – and how improving patient convenience can result in product differentiation and revenue growth. Register now.

Novo Nordisk adds bioelectronics, biosensors and stimuli-responsive delivery devices to scope of MIT pact

By Nick Paul Taylor

Novo Nordisk has expanded its drug delivery collaboration with Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH). Building on advances such as the SOMA robotic pill, the partners will work on bioelectronics, biosensors and stimuli-responsive delivery devices.

Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test

By Nick Paul Taylor

Progenity is advancing its oral biologic drug delivery project using the successful completion of its study in healthy volunteers as a launchpad for a clinical trial in patients with ulcerative colitis.

MHRA request about ultrasound activation system holds up Exact Therapeutics’ solid tumor trial

By Nick Paul Taylor

Exact Therapeutics’ attempt to get its solid tumor clinical trial back on track has hit a snag, with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) asking for information on the ultrasound system used to activate the therapy.

Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

By Fraiser Kansteiner

The FDA has delayed its decision on Incyte’s Opzelura in vitiligo by three months. The regulator now plans to deliver a verdict on the topical JAK inhibitor, also known as ruxolitinib cream, by July 18, Incyte said in a release.

Webinar: Key Challenges & Opportunities in the Process Scale-Up of Oral Solid Dosage Forms

Tuesday, April 5 | 11am ET / 8am PT

Join this webinar to hear experts share insights into faster drug product manufacturing in a large-scale setting and discuss upcoming trends in oral solid dose form manufacturing. Register Now.

Resources

Industry Report: The Top Four Barriers to Successful KOL Engagement

eBook: Leveraging Clinical Data for Study Success

Sponsored by: Medidata, a Dassault Systèmes company

The landscape of clinical trials has been permanently changed. Today's trials require sponsors to modernize their use of technology and data to adapt. This eBook provides an overview of how sponsors can empower trials with real-time performance data to improve study integrity, reduce risks, optimize patient safety, and increase trial success rates.